Stay updated on Switching to Cabotegravir and Rilpivirine: Clinical Trial
Sign up to get notified when there's something new on the Switching to Cabotegravir and Rilpivirine: Clinical Trial page.

Latest updates to the Switching to Cabotegravir and Rilpivirine: Clinical Trial page
- Check2 days agoNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange Detected403 Forbidden error header now appears on the page, with a Home link and a Revision: v3.7.0 notice, replacing the previous study content and signaling that the page is inaccessible.SummaryDifference21%

- Check37 days agoChange DetectedThe page adds a note about a 2016 NIH grant/contract. It also updates the revision to v3.6.6, replacing the previous v3.6.5.SummaryDifference0.0%

- Check58 days agoChange DetectedThe site’s revision tag was updated from v3.6.4 to v3.6.5, reflecting a new release version of the software or page framework.SummaryDifference0.0%

- Check73 days agoChange DetectedThe page's revision label was updated from v3.6.3 to v3.6.4. This signals a new software release rather than changes to the study details or page content.SummaryDifference0.0%

- Check87 days agoChange DetectedAdded two new study locations: Ciudad Autonoma Buenos Aires, Argentina, C1405CKC and Guadajalara, Mexico, 44280. Removed previously listed Ciudad Autonoma de Bueno, Argentina, C1405CKC and Guadalajara, Mexico, 44280, indicating a replacement/update of site entries.SummaryDifference0.1%

- Check94 days agoChange DetectedPage revision updated from v3.6.2 to v3.6.3.SummaryDifference0.0%

Stay in the know with updates to Switching to Cabotegravir and Rilpivirine: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Switching to Cabotegravir and Rilpivirine: Clinical Trial page.